European Orphan Designation for DAY101 for treatment of glioma

DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signalling pathway. It will be investigated in a Phase 2 clinical trial (FIREFLY-1) of patients with recurrent or progressive low-grade glioma.

Biospace Inc.